More Ranbaxy woes

Share this article:

The FDA has put Ranbaxy Laboratories on notice.

Again.

Bloomberg reports that the US regulator says a recent inspection shows a Punjab, India, plant that makes 60% to 70% of the company's active ingredients is failing to make the grade.

The company agreed to shell out $500 million over fraud allegations in May, and Bloomberg notes that the US has already banned items from three Ranbaxy plants from entering the country.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.